Citigroup’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Citigroup’s Portfolio INFI Stock Details INFI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-33,000	Closed	-$536K	–	7037
2013 Q2	$536K	Buy	+33,000	New	+$1.02M	﹤0.01%	3435

Other funds holding INFI

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citigroup's INFI Position: Q1 2023 in Review

Citigroup sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q1 2023, closing a stake of 107 shares — an estimated $59 sold.

Citigroup first reported a position in INFI in Q2 2013 and held it in 24 quarters. The position peaked at $689K in Q3 2013. 53 funds tracked by Wall St. Rank hold INFI as of Q1 2023.

Citigroup reported no remaining Infinity Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
Citigroup sold 107 Infinity Pharmaceuticals, Inc. shares in Q1 2023, an estimated $59.
Citigroup first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 24 quarters.
Citigroup's Infinity Pharmaceuticals, Inc. position peaked at $689K in Q3 2013.
53 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q1 2023.

Based on Citigroup's 13F filing for Q1 2023, filed 11 May 2023.